ALSO NOTED: Altea garners $30M in venture money; Par loses patent fight; Ranbaxy JV unveils diabetes drug; and much more

> Altea Therapeutics raised more than $30 million in venture capital for development of pain management and diabetes patches. The Series C financing was led by Aperture Venture Partners, but includes Altea's Series B investors Domain, Venrock, and vSpring Capital. Release

> Par Pharmaceutical loses Zofran patent fight with GlaxoSmithKline. Release

> Ranbaxy's JV with Japan's Nippon Chemiphar unveils maiden diabetes drug. Story

> Human tissue supplier CryoLife agrees to pay $23 million to settle lawsuit over contamination. Report

> Biolex Therapeutics acquires LemnaGene, a French biotech startup researching protein development.  Release

> Boehringer Ingelheim wins regulatory nod for tipranavir, a non-peptidic protease inhibitor. Release

> Cortex launches Phase IIa studies of  Ampakine CX717 for ADHD and Alzheimer's Disease. Release

> Savient to set Phase III parameters with FDA on gout drug. Story

> British vaccine firm Acambis is starting trials of a vaccine to prevent infections from a new strain of clostridium difficile that has spawned outbreaks in at least 15 U.K. hospitals. Report

and finally...Sorry, herbal enthusiasts, researchers says Echinacea is a dud against colds. Article

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.